Close Menu

NEW YORK – An analysis from an international team suggests testing for pathogenic BRCA1/2 variants in women from the general population would be cost-effective for half a dozen countries with a range of income levels, while preventing a significant number of breast and ovarian cancer cases and deaths.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.